Background: Sarcoidosis is a systemic disease, characterised by non-caseating granulomas in various organs. Liver involvement is not an
tests, diffusing capacity of the lungs for carbon monoxide/alveolar volume (DLCO/VA) tests, chest X-ray, thorax computed tomography (CT) and fiberoptic bronchoscopy (FOB).
Laboratory investigations included complete blood count, liver function, renal function tests, serum calcium, 24-hour urinary calcium, erythrocyte sedimentation rate, C-reactive protein and angiotensinconverting enzyme (ACE). Abnormal liver or renal function tests, high serum ACE, hypercalcaemia and hypercalciuria were considered to be present if they were above the normal range. Chest roentgenograms were staged according to the DeRemee as follows.
• Stage 0: normal.
• Stage I: bilateral hilar lymphadenopathy.
• Stage II: bilateral hilar lymphadenopathy and parenchymal involvement.
• Stage III: parenchymal involvement only.
• Stage IV: pulmonary fibrosis. • no liver involvement (NLI);
• limited liver involvement (LLI): positive liver biopsy; and
• diffuse liver involvement (DLI): positive liver biopsy.
Diffuse hepatic involvement was identified by the presence of three or more granulomas, whereas patients with limited disease had fewer than three granulomas detected by ultrasound (US) and/or CT. Extrapulmonary organ involvement was classified into two groups as: fewer than three, and three or more organs involved. 
Discussion
Sarcoidosis affecting the liver can cause significant morbidity. The incidence of hepatic sarcoidosis is underestimated because other clinical manifestations, especially pulmonary, skin or eye symptoms, tend to dominate the clinical picture. In addition, the symptoms are often nonspecific and are therefore not attributed to hepatic involvement, even in patients with previous diagnosis of sarcoidosis. 4 In the current study, hepatic involvement was present in 45.7% of sarcoidosis patients.
We have observed that diffuse liver sarcoidosis leads to a more severe prognosis compared with patients without or with limited liver disease.
Diffuse hepatic sarcoidosis appears to be a significant factor for progressive disease. The prognosis was approximately five times worse in the DLI group compared to patients without liver disease and three times worse than the LLI patients.
On the other hand, the second aspect of our study was that extrapulmonary organ involvement was more frequent and severe in the DLI group compared to the NLI and LLI patients, contributing to the worse prognosis. Concomitant extra-pulmonary involvement rate was highest in the DLI group, followed by LLI and NLI patients. The most frequently involved organs were the lungs, skin and eyes. Neville et al. have reported a similar in frequency for concomitant extra-pulmonary involvement their study. 10 This study clearly denotes that the higher the granuloma burden, caused by diffuse liver involvement, the worse the prognosis and the more severe is the extra-pulmonary organ involvement. This is supported by the fact that DLI patients showed the most unfavourable clinical implications compared with LLI and NLI groups. As the results of our study suggest, extra-pulmonary organ involvement also depends upon the burden of non-caseating granulomas.
Hypercalcaemia is reported to be present in approximately 27% of the patients with sarcoidosis, with a range of 2-63%. Depending on the published studies, nearly 27% (range: 2-63%) of the sarcoidosis patients have hypercalcaemia. The main cause in the difference of the incidence of hypercalcaemia may be an ondulating course of sarcoidosis, so that the high levels may be missed clinically when serum calcium is not measured or when the patients are in remission.
Hypercalcaemia in sarcoidosis is due to the uncontrolled synthesis of 1,25-dihydroxyvitamin D3 by macrophages. 1,25-dihydroxyvitamin D3 leads to an increased absorption of calcium from the intestine and resorption of the bone. The extremely low incidence of hypercalcaemia in our patients may be related to the decrease in 25-alpha-hydroxylase activity in hepatocytes caused by the hepatic involvement in these patients. In the current study, the granulomas were located most commonly at the periportal area. This finding is compatible with the literature. the absence of extensive fibrosis and regenerative nodules in addition to benign liver pathologies such as adenomas suggests that liver sarcoidosis is weakly associated with malignancy, as is the case in our patients. 5, 16, 17 We are aware of the limitations of our study. This is a retrospective study with a small sample size. Further prospective studies including more patients with histopathologically diagnosed liver biopsy samples may be needed to define the limited and diffuse hepatic sarcoidosis more precisely, thereby enlightening the clinical features and the prognosis of these patients. The follow-up interval may be considered short, but it is well known that most of the prognostic risk factors for progressive disease become apparent within two years of diagnosis;
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follow up was approximately 10 years in our patients. [20] [21] [22] Furthermore, although the clinicians were very experienced, the biopsy samples may be inadequate, may not represent the disease site and therefore may not identify the non-caseating granulomas.
Diffuse liver involvement in sarcoidosis appears to be a significant factor for progressive disease. The severe prognosis is probably associated with the high granuloma burden in patients with diffuse disease. This finding is also supported by the raised levels of serum ACE levels, reflecting the high granuloma burden in these two groups of patients with limited and diffuse disease. Our results emphasise the significance of identifying diffuse hepatic involvement in regard to prognosis and a progressive disease. Positive liver biopsy and radiological investigations for the diagnosis of limited or diffuse liver involvement may be useful to predict the prognosis. The incidence of severe extrapulmonary is also significantly higher in these patients contributing to the worse prognosis. This finding is unique because previous studies have not reported that diffuse liver involvement would be associated with a progressive disease and a more severe extrapulmonary organ involvement. Clinicians should be aware that diffuse hepatic involvement may indicate a worse prognosis. ■
